Satsuma Pharmaceuticals,a clinical-stage biopharmaceutical company has appointed Mutya Harsch (pictured) to its board of directors, effective immediately. Harsch brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to Satsuma. She currently serves as general counsel, chief legal officer and secretary of Vyne Therapeutics, a publicly traded biopharmaceutical company.
Prior to joining Vyne Therapeutics, Harsch served as general counsel and chief legal officer of Foamix Pharmaceuticals. Earlier in her career, she practiced law at Cooley’s, Davis Polk & Wardwell as well as Warner Chilcott.